AB2 Bio has entered into an agreement with Nippon Shinyaku granting exclusive U.S. commercialization rights for Tadekinig alfa, a treatment for a life-threatening rare disease, while securing up to $36 million in initial payments and potential future earnings of up to $650 million.

Information on the Target

AB2 Bio Ltd., a biotechnology firm based in Lausanne, Switzerland, specializes in developing innovative therapies for severe systemic hyperinflammatory diseases linked to IL-18 cytokine dysregulation. Notably, the company is focused on treating Primary Monogenic IL-18 driven Hyperinflammatory Syndrome, a rare and potentially life-threatening condition primarily affecting young patients with specific genetic mutations (NLRC4 and XIAP). Tadekinig alfa, AB2 Bio's flagship treatment, works as a recombinant human IL-18 Binding Protein (IL-18 BP), designed to bind and inhibit the overactive IL-18, designed to mitigate dangerous inflammation.

Under a new agreement with Nippon Shinyaku Co. Ltd., AB2 Bio has secured an option that allows Nippon Shinyaku to obtain exclusive U.S. rights for the commercialization of Tadekinig alfa specifically for this severe indication. As AB2 Bio progresses towards filing a Biologics License Application (BLA) for the treatment, it retains rights for other indications of Tadekinig alfa within the U.S. and globally.

Industry Overview

In the United States, the pharmaceutical industry is a multi-billion-dollar sector characterized by robust growth and innovation. The market is primarily driven by advancements in biotechnology, particularly for rare diseases—conditions defined by their low prevalence but often severe and unfulf